Cargando…

PB2141: CLINICOPATHOLOGICAL FEATURES AND OUTCOME OF CD5 POSITIVE DIFFUSE LARGE B CELL LYMPHOMA AND THE SIGNIFICANCE OF CD5 EXPRESSION STRENGTH: 10-YEAR SINGLE CENTER EXPERIENCE

Detalles Bibliográficos
Autores principales:	Vukovic, V., Karan-Djurasevic, T., Otasevic, V., Sarac, S., Sabljic, N., Antic, D., Djurasinovic, V., Tomic, K., Mihaljevic, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429660/ http://dx.doi.org/10.1097/01.HS9.0000851396.39065.72

Ejemplares similares

PB2086: CHRONIC LYMPHOPROLIFERATIVE DISORDER OF NK CELLS WITH LIVER INFILTRATION
por: Otasevic, V., et al.
Publicado: (2022)

PB2162: INCREASED OXIDATIVE STRESS IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Antic, D., et al.
Publicado: (2022)

PB2662: ABO BLOOD GROUP TYPE AND RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH LYMPHOMA
por: Otasevic, Vladimir, et al.
Publicado: (2023)

PB2260: FIVE-YEAR SINGLE-CENTER EXPERIENCE IN THE TREATMENT OF ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA WITH ABVD
por: Vukovic, Vojin, et al.
Publicado: (2023)

PB1956: ANALYSIS OF CLINICAL COURSE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND COMPLEX KARYOTYPE – SINGLE CENTRE EXPERIENCE
por: Sarac, Sofija, et al.
Publicado: (2023)

PB1917: EXPRESSION OF THE LONG NON-CODING RNA MALAT1 IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Karan-Đurašević, Teodora, et al.
Publicado: (2023)

PB2180: TREATMENT CHALLENGES OF COEXISTING MYELOID AND LYMPHOID NEOPLASM- A CASE REPORT
por: Smiljanic, Mihailo, et al.
Publicado: (2023)

PB1832: ARTERIAL THROMBOSIS AND ACUTE MYELOID LEUKEMIA – IS THERE A CONNECTION?
por: Pantic, N., et al.
Publicado: (2022)

PB1821: THE INFLUENCE OF BCL2, BAX, BAX/BCL2 RATIO AND MDR1 GENE EXPRESSION ON PROGNOSIS OF ADULT DE NOVO ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE
por: Pravdic, Zlatko, et al.
Publicado: (2023)

PB1919: MATURE B-CELL NEOPLASMS CD5 NEGATIVE: CONFRONTATION CYTOMETRY-CYTOLOGY
por: Cheikh, Hanen Ben, et al.
Publicado: (2023)

P1694: THROMBOSIS RISK ASSESSMENT IN LYMPHOMA PATIENTS - PROSPECTIVE PILOT SUDY
por: Antic, D., et al.
Publicado: (2022)

PB2271: ANALYSIS OF CLINICAL AND LABORATORY PARAMETERS IN PATIENTS WITH PRIMARY ORBITAL AND ADNEXAL MUCOSSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA- A TWENTY YEARS SINGLE CENTRE EXPERIENCE
por: Smiljanic, Mihailo, et al.
Publicado: (2023)

PB1951: INVESTIGATION OF THE RELATIONSHIP BETWEEN CD56 AND CD117 EXPRESSIONS AND CLINICAL AND LABORATORY FINDINGS IN MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS
por: Akkurd, D. M., et al.
Publicado: (2022)

PB2127: NO IMPACT OF STATIN USE ON RESPONSE AND SURVIVAL RATES IN NEWLY DIAGNOSED DLBCL PATIENTS TREATED WITH R-DA-EPOCH
por: Sabljic, A., et al.
Publicado: (2022)

PB2400: THE EFFECT OF BONE MARROW CD4/CD8+ RATIO ON RESPONSE TO TREATMENT AND SURVIVAL IN LYMPHOMAS
por: Can Cavdar, Vahit, et al.
Publicado: (2023)

Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients
por: Otasevic, Vladimir, et al.
Publicado: (2022)

PB2031: CD269, CD319 EXPRESSION ON MALIGNANT PLASMA CELLS AND SOLUBLE BCMA, SLAMF7 PROTEINS COMPARATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
por: Startsev, A., et al.
Publicado: (2022)

PB2582: WHY INFECTIOUS COMPLICATIONS ARE STILL THE MAIN CAUSE OF MORTALITY DURING THE TREATMENT OF PATIENTS WITH ACUTE LEUKEMIA?
por: Vidovic, Ana, et al.
Publicado: (2023)

PB1858: INFLUENCE OF INFLAMMATION ON ANGIOGENIC FACTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Mitrović Ajtić, O., et al.
Publicado: (2022)

PB2210: FAVORABLE OUTCOME AFTER SECOND CD19 CAR T INFUSION OF AN IDENTICAL PRODUCT: HOST ENVIRONMENT AND DISEASE CHARACTERISTICS DETERMINE THE OUTCOME OF TREATMENT
por: Frölich, L., et al.
Publicado: (2022)

PB1717: CD19-NEGATIVE B- ACUTE LYMPHOBLASTIC LEUKEMIA: WHAT CHALLENGES?
por: Siala, Nour, et al.
Publicado: (2023)

PB1956: EVALUATION OF AN INNOVATIVE NEW METHOD FOR QUANTITATION OF PLASMA CELLS ON CD138 IMMUNOHISTOCHEMISTRY
por: Gantana, E., et al.
Publicado: (2022)

PB1817: PROGNOSTIC SIGNIFICANCE OF CD200 ON ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA AND ITS MECHANISM
por: Quan, X., et al.
Publicado: (2022)

PB1794: EFFECT OF HYPOXIA ON CD47 EXPRESSION IN HUMAN ACUTE MYELOID LEUKEMIA CELL LINES
por: Wang, C., et al.
Publicado: (2022)

PB2072: CIRCULATING CD71+ MYELOID PRECURSORS IN MGUS AND MULTIPLE MYELOMA: A PROSPECTIVE SURVEY
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

PB1917: PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF ELEMENTS OF THE ADAPTIVE IMMUNITY IN THE MICROENVIRONMENT OF MYELODYSPLASTIC SYNDROMES TREATED WITH 5-AZACITIDINE
por: Tsakiraki, Z., et al.
Publicado: (2022)

PB2220: ATRIAL FIBRILLATION IS FREQUENT IN PATIENTS WITH MYELOFIBROSIS AND MIGHT BE SUB-OPTIMALLY TREATED
por: Lucijanic, Marko, et al.
Publicado: (2023)

PB2155: TARGETING NEUROBIOLOGICAL MECHANISMS IN PATIENTS WITH MULTIPLE MYELOMA HAS IMPROVED THEIR PLASMACYTOID DENDRITIC CELLS CD123+, B LYMPHOCYTE MEMORY CELLS CD27+, VAGAL ACTIVITY AND DISTRESS.
por: Kotoucek, Pavel, et al.
Publicado: (2023)

PB2352: CONSOLIDATION OF ERN-EUROBLOODNET: THE EUROPEAN REFERENCE NETWORK ON RARE HEMATOLOGICAL DISEASES FIRST 5 YEARS OF IMPLEMENTATION
por: Mañú Pereira, M. D. M., et al.
Publicado: (2022)

PB2052: CLINICOPATHOLOGIC VARIABLES AFFECTING DISEASE OUTCOME IN PRIMARY MYELOFIBROSIS. A SINGLE CENTER EXPERIENCE.
por: Elkourashy, S., et al.
Publicado: (2022)

P1653: INFLAMMATION MEDIATED THROMBUS FORMATION IN LYMPHOMAS
por: Antic, Darko, et al.
Publicado: (2023)

PB1912: MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND ASSOCIATED 5Q DELETION TO 13Q DELETION
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

PB1811: BIOLOGIC AND CLINICAL SIGNIFICANCE OF CD7 ABERRANT EXPRESSION IN ACUTE MYELOID LEUKEMIA: A POOR PROGNOSIS MARKER
por: Charfi, H., et al.
Publicado: (2022)

PB1814: RARE PHENOTYPE WITH CD33 ABSENT IN ACUTE MYELOID LEUKEMIA MIMICKING MRD POSITIVITY: A CASE REPORT
por: O Marani, L., et al.
Publicado: (2022)

PB2441: CD34+ CELL DOSE EFFECTS ON CLINICAL OUTCOMES OF ALLO-HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)
por: Zhou, Shengnan, et al.
Publicado: (2023)

PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY
por: Cho, Seok-Goo, et al.
Publicado: (2023)

PB1777: THE AUTOMATED DATABASE-GUIDED STUDY OF THE PHENOTYPIC PROFILE IN CD34+ CD117+ HLADR+ PRECURSORS PROVIDES A SIMPLE AND RELIABLE STRATEGY FOR RAPID IDENTIFICATION OF CBF-MYH11+ ACUTE MYELOID LEUKEMIA.
por: Piñero, Paula, et al.
Publicado: (2023)

PB2286: INFLUENCE OF ANTI-CD20 MONOCLONAL ANTIBODY THERAPY ON THE OUTCOME OF CORONAVIRUS INFECTION COVID-19 IN PATIENTS WITH LYMPHOPROLIFERATIVE DISEASES
por: Zotina, E., et al.
Publicado: (2022)

PB2439: EARLIER ENGRAFTMENT WITHOUT INCREASE OF GVHD IN HIGHER DOSE OF CD34+ CELLS IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Tan, Tran-Der, et al.
Publicado: (2023)

PB2351: ANXIETY AT THE HEMATOLOGIST
por: Trojan, S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5gqbkdj8agrliv121fe1qc6vso